Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA health claims rulings may be subject of House Oversight hearing -- Rep. Burton.

This article was originally published in The Tan Sheet

Executive Summary

FDA HEALTH CLAIMS RULINGS "FLOUT" WILL OF CONGRESS, REP. BURTON asserts in an Aug. 13 letter to FDA Acting Commissioner Michael Friedman, MD. Rep. Dan Burton (R-Ind.), chairman of the House Government Reform & Oversight Committee, says FDA's position on the "authoritative statements" health and nutrient content claims provisions in the FDA Modernization Act "undo the good work" Congress has done in the health claims sections of the law. FDA issued nine interim final rules June 22 withholding approval of several proposed health claims included in notification letters filed with the agency by Salt Lake City- based Weider Nutrition International ("The Tan Sheet" June 29, pp. 1-9).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel